Report ID :10293921 |
Published Date : 21 Oct 2022 |
Report Format : |
Delivery Timeline :48-72 Business Hours
REPORT HIGHLIGHT
The antibiotics market is estimated to represent a global market of USD 43.9 billion by 2017 with growth rate of 4.9%.
Market Dynamics
Across the world, the number of individuals suffering from chronic diseases is on the rise. As per the World Health Organization (WHO), chronic disease accounts for more than 60% of all deaths, i.e. 36 million deaths out of 57 million global deaths. Antibiotics are increasingly used in the management of infectious and chronic conditions such as asthma, cystic fibrosis, COPD, and others. Thereby, the demand for antibiotics is more likely to increase for the treatment of these disease conditions, as the incidences of chronic diseases pick up. Meanwhile, numerous national and international initiatives aimed at financially incentivizing the R&D activities of antibiotics. Some of the major initiatives are New Drugs for Bad Bugs (ND4BB) program by the Innovative Medicines Initiative (IMI), Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), and Broad Spectrum Antimicrobials Program and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Such types of initiatives would, in turn, support the growth over the study period.
However, growing concern over antibiotic overuse is expected to hinder the industry growth to some extent. Overuse of these drugs may develop resistance to antimicrobial medications which is considered to be a serious public health threat to the world. According to the statement by European Centre for Disease Prevention and Control (ECDC) in November 2012, around 25,000 people die every year due to antibiotic-resistant bacterial infections in European countries.
Inhibitor Type Takeaway
By inhibitor types, the industry is divided into Protein Synthesis, Cell Wall, DNA, RNA, and other inhibitors. Cell wall synthesis inhibitors accounted for the highest share of the total market. In 2017, the segment captured around 42% share of the overall market and is projected to dominate the industry. This drug class includes antibiotics such as penicillin, cephalosporin, and Carbapenems. These are one of the most important groups of antibiotics and offers the greatest activity against gram-positive and negative bacteria. Cell wall synthesis inhibitors act by prohibiting the synthesis of the peptidoglycan layer, which is a crucial element for the structural activity of the cell wall. However, RNA segment is projected to grow with the highest growth rate and is pegged to register a 6.2% CAGR in terms of value.
Drug Class Takeaway
Drug class is categorized into Fluoroquinolones, Cephalosporin, Penicillin, Macrolides, Carbapenems, Aminoglycosides, and other. Growing by approximately 3% to 4% every year, cephalosporin drug class is the highest revenue generating segment throughout the study period. The growth of this bactericidal agent is majorly attributed to the rising demand for 4th and 5th generation therapeutics such as Ceftaroline fosamil, Cefpirome, and Ceftobiprole. On another side, aminoglycosides captured less than 5% share (i.e. lowest) of the global industry in 2017. Others segment comprise of tetracyclines, sulphonamides, monoclonal antibodies, imidazole, and many more.
Regional Takeaway
Regionally, Asia Pacific region is accounted for the largest share of the worldwide market. In 2017, the region captured almost 47% share of the overall market. Increasing prevalence of infectious and chronic diseases coupled with rising interest of global players to invest in this market support the regional growth. While the industry is on a high growth trajectory in developing regions, demand and advancement in regions like North America, and Europe is constantly increasing. Growth is mainly supported by the favorable reimbursement policies, rising demand for branded therapeutics, and increasing R&D activities.
Key Vendor Takeaway
Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG, and AstraZeneca are studied in detail. The industry is largely controlled by well-established companies even though the share of small-scale players is noticeable too. Companies such as Johnson & Johnson, Pfizer, and Novartis are considered to be a giant player in this market owing to their strong product pipeline and strategic expansion.
For example, Pfizer, Inc. offers a broad range of antibiotics that includes Diflucan, Zithromax/Zmax, Unasyn, Vfend, Sulperazon, Tygacil, and others. Of these, in 2015, antibiotics such as Zyvox (USD 883 million), and Vfend (USD 682 million) recorded the highest revenue. The industry exhibits a high level of competition. Since the market is in the mature phase, barriers to entry are low. Still, in such a fragmented landscape, most antibiotic companies compete only with other local or regional players.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY INHIBITOR TYPE
Protein Synthesis
Cell Wall
DNA
RNA
Others
MARKET, BY DRUG CLASS
Fluoroquinolones
Cephalosporin
Penicillin
Macrolides
Carbapenems
Aminoglycosides
Other
MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
